The identification of PI3K, MAPK and NFκB through IPA analysis as central nodes of the Rb-dependent hypoxia signal in the neurological disease network leads to the intriguing possibilities of new drug targets for late stage prostate cancer (Figure 4C). This evidence concerns the gene RB1 and nervous system disorder.